# Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

Study · id `cardio:ct-nct01059825` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01059825](<https://clinicaltrials.gov/study/NCT01059825>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01059825

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 375 participants.

## Technical summary

Registry record NCT01059825. Randomized; double masking; primary purpose treatment. Start 2010-02-24 (actual); primary completion 2011-01-20 (actual). Results posted on 2017-10-04.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 375 participants (enrolled count; ClinicalTrials.gov record NCT01059825, source copy `cardio:ctgov-nct01059825-2018-09-13`, retrieved 2026-10-26)
- Started: 2010-02-24 (actual) (ClinicalTrials.gov record NCT01059825, source copy `cardio:ctgov-nct01059825-2018-09-13`, retrieved 2026-10-26)
- Primary completion: 2011-01-20 (actual) (ClinicalTrials.gov record NCT01059825, source copy `cardio:ctgov-nct01059825-2018-09-13`, retrieved 2026-10-26)
- Completion: 2011-01-20 (actual) (ClinicalTrials.gov record NCT01059825, source copy `cardio:ctgov-nct01059825-2018-09-13`, retrieved 2026-10-26)
- Results first posted: 2017-10-04 (ClinicalTrials.gov record NCT01059825, source copy `cardio:ctgov-nct01059825-2018-09-13`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01059825-2018-09-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Placebo to Ertugliflozin
- Intervention (Drug): Ertugliflozin 1 mg
- Intervention (Drug): Ertugliflozin 5 mg
- Intervention (Drug): Ertugliflozin 25 mg
- Intervention (Drug): Sitagliptin 100 mg
- Intervention (Drug): Placebo to Sitagliptin
- Intervention (Drug): Metformin
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Pfizer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)
- Registry lists this organization as a collaborator: Pfizer (`cardio:org-pfizer`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin (`cardio:pubmed-25754396`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ffd4a1afc7a5f1f5c1071c64220985652f91c8356564c07c10e130e2cf41a35a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
